Fusion Pharmaceuticals (NASDAQ:FUSN – Get Free Report) and Exelixis (NASDAQ:EXEL – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.
Earnings & Valuation
This table compares Fusion Pharmaceuticals and Exelixis’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fusion Pharmaceuticals | $1.46 million | 177.23 | -$87.61 million | ($1.93) | -1.94 |
| Exelixis | $1.61 billion | 4.39 | $182.28 million | $0.51 | 43.57 |
Exelixis has higher revenue and earnings than Fusion Pharmaceuticals. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Profitability
This table compares Fusion Pharmaceuticals and Exelixis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fusion Pharmaceuticals | -26,656.52% | -52.38% | -39.54% |
| Exelixis | 9.58% | 6.53% | 5.33% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Fusion Pharmaceuticals and Exelixis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fusion Pharmaceuticals | 0 | 0 | 6 | 0 | 3.00 |
| Exelixis | 0 | 5 | 11 | 0 | 2.69 |
Fusion Pharmaceuticals presently has a consensus target price of $10.80, suggesting a potential upside of 188.00%. Exelixis has a consensus target price of $25.24, suggesting a potential upside of 13.57%. Given Fusion Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Fusion Pharmaceuticals is more favorable than Exelixis.
Institutional & Insider Ownership
72.9% of Fusion Pharmaceuticals shares are held by institutional investors. Comparatively, 93.1% of Exelixis shares are held by institutional investors. 7.8% of Fusion Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Exelixis beats Fusion Pharmaceuticals on 10 of the 14 factors compared between the two stocks.
About Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
About Exelixis
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
